Mitsubishi UFJ Asset Management Co. Ltd. Sells 2,529 Shares of Masimo Co. (NASDAQ:MASI)

Mitsubishi UFJ Asset Management Co. Ltd. decreased its stake in shares of Masimo Co. (NASDAQ:MASI) by 39.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,924 shares of the medical equipment provider’s stock after selling 2,529 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Masimo were worth $672,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of MASI. Smartleaf Asset Management LLC boosted its position in shares of Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 60 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. increased its holdings in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Masimo by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after buying an additional 82 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Masimo by 0.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock valued at $1,728,000 after buying an additional 83 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on MASI. Wells Fargo & Company lifted their price objective on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Raymond James upped their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Piper Sandler raised their target price on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Up 2.3 %

Shares of NASDAQ MASI opened at $171.48 on Thursday. The company has a market cap of $9.27 billion, a price-to-earnings ratio of 118.26 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The stock has a 50-day moving average price of $174.47 and a two-hundred day moving average price of $162.55.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analysts’ expectations of $593.35 million. As a group, analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.